Company profile for Vanqua Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vanqua Bio is helping usher in a new era of hope for patients living with neurodegenerative disorders. Toward that end, we have assembled a world-class team of scientists, board members, and advisors with proven capabilities in advancing molecules that become transformative medicines. Combining the key ingredients of scientific expertise, creativity, and experience, our team embraces the challenge and responsibility of improv...
Vanqua Bio is helping usher in a new era of hope for patients living with neurodegenerative disorders. Toward that end, we have assembled a world-class team of scientists, board members, and advisors with proven capabilities in advancing molecules that become transformative medicines. Combining the key ingredients of scientific expertise, creativity, and experience, our team embraces the challenge and responsibility of improving the lives of patients with PD, GD, ALS, AD and related neurological diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2430 N Halsted Street Suite 110 Chicago IL 60614
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-licenses-vanqua-bios-immune-disorder-drug-up-106-billion-2025-10-24/

REUTERS
25 Oct 2025

https://www.globenewswire.com/news-release/2025/10/02/3160240/0/en/Vanqua-Bio-Highlights-Positive-Interim-Data-from-its-Ongoing-Phase-1b-Clinical-Trial-of-VQ-101-an-Allosteric-Activator-of-GCase-for-the-Treatment-of-GBA-Parkinson-s-and-Related-Dis.html

GLOBENEWSWIRE
02 Oct 2025

https://www.globenewswire.com/news-release/2025/06/03/3092614/0/en/Vanqua-Bio-to-Present-at-Upcoming-Scientific-Conferences.html

GLOBENEWSWIRE
03 Jun 2025

https://www.globenewswire.com/news-release/2025/03/27/3050414/0/en/Vanqua-Bio-to-Present-at-the-AD-PD-2025-International-Conference.html

GLOBENEWSWIRE
27 Mar 2025

https://www.globenewswire.com/news-release/2024/12/05/2992377/0/en/Vanqua-Bio-to-Present-Pre-Clinical-Data-on-VQ-201-a-Next-Generation-C5aR1-Antagonist-for-the-Treatment-of-Inflammatory-Disorders.html

GLOBENEWSWIRE
05 Dec 2024

https://www.globenewswire.com//en/news-release/2024/10/09/2960411/0/en/Vanqua-Bio-Announces-Positive-Interim-Results-from-Phase-1-Clinical-Trial-of-VQ-101-an-Orally-Administered-Brain-Penetrant-Allosteric-Activator-of-GCase-for-the-Treatment-of-GBA-Pa.html

GLOBENEWSWIRE
09 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty